Big change in segmental/geographic reporting makes models hard to maintain.
Big change in segmental/geographic reporting makes models hard to maintain.
1. Click Here: amazon.com/dp/B0H5K6943N
2. Clip the coupon under the price on the page
1. Click Here: amazon.com/dp/B0H5K6943N
2. Clip the coupon under the price on the page
Find them here: https://ow.ly/uzb75105tSp
#echosky #cardiosky
Find them here: https://ow.ly/uzb75105tSp
#echosky #cardiosky
📆 19/11/2026
🕦 12:30
🎤 Scott Perry & Miquel Llompart (UPF)
🚩 Sala 52.939 (UPF) i també en línia
ℹ️ tuit.cat/3djSz
📆 19/11/2026
🕦 12:30
🎤 Scott Perry & Miquel Llompart (UPF)
🚩 Sala 52.939 (UPF) i també en línia
ℹ️ tuit.cat/3djSz
#renalpath #kidneypath #pathology #renal
#renalpath #kidneypath #pathology #renal
🌟 Hiddo Heerspink on finerenone in FSGS (FIND-CKD): see albuminuria and proteinuria 🔎
👉 https://journals.lww.com/jasn/pdf/10.1681/asn.0000001333~finerenone-in-patients-with-focal-segmental
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrial
🌟 Hiddo Heerspink on finerenone in FSGS (FIND-CKD): see albuminuria and proteinuria 🔎
👉 https://journals.lww.com/jasn/pdf/10.1681/asn.0000001333~finerenone-in-patients-with-focal-segmental
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrial
https://doi.org/10.1038/s41586-026-11258-0
@miao-yu.bsky.social
https://doi.org/10.1038/s41586-026-11258-0
@miao-yu.bsky.social
ɪɴ ᴏʀᴅᴇʀ ꜰᴏʀ ᴛᴀᴋɪɴɢ 𝐔𝐩-𝐓𝐨-𝐃𝐚𝐭𝐞 🆕ʀᴇꜱᴘᴏɴꜱɪʙɪʟɪᴛʏ ᴡɪᴛʜ ɢᴇɴᴇʀᴀʟ ᴀɪꜱ, ᴡʜɪᴄʜ ᴏɴᴇ ᴏꜰ Qᴜᴏᴛᴇꜱ ᴄᴀɴ ʏᴏᴜ ᴛᴀᴋᴇ ᴀꜱ ᴀɴꜱᴡᴇʀᴀʙɪʟɪᴛʏ?
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
ɪɴ ᴏʀᴅᴇʀ ꜰᴏʀ ᴛᴀᴋɪɴɢ 𝐔𝐩-𝐓𝐨-𝐃𝐚𝐭𝐞 🆕ʀᴇꜱᴘᴏɴꜱɪʙɪʟɪᴛʏ ᴡɪᴛʜ ɢᴇɴᴇʀᴀʟ ᴀɪꜱ, ᴡʜɪᴄʜ ᴏɴᴇ ᴏꜰ Qᴜᴏᴛᴇꜱ ᴄᴀɴ ʏᴏᴜ ᴛᴀᴋᴇ ᴀꜱ ᴀɴꜱᴡᴇʀᴀʙɪʟɪᴛʏ?
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
bsky.app/profile/abso...
#KICR highlights
#KICR highlights
🔗 Read the full story on GazeWire
#UAE #Biotech #Healthcare #GazeWire
🔗 Read the full story on GazeWire
#UAE #Biotech #Healthcare #GazeWire
The global focal segmental glomerulosclerosis (FSGS) treatment market was valued at US$ 2.39 billion in 2025 and is expected to reach US$ 3.98 billion by 2034, registering a CAGR of 5.80% during…
The global focal segmental glomerulosclerosis (FSGS) treatment market was valued at US$ 2.39 billion in 2025 and is expected to reach US$ 3.98 billion by 2034, registering a CAGR of 5.80% during…